Podravka Q1 22 - Published results above RBIe in Q1 22
Podravkas reported Q1 22 figures above RBIe on unadjusted levelsAs expected, operating profitability decreased yoy
Pharmaceuticals segment was the main catalyst behind lower EBITDA and EBIT yoy
Russia-Ukraine crisis negatively impacted profitability of the Pharmaceuticals segment
The Institutional Equity Research team of Raiffeisen Bank International AG covers 85 stocks from Austria, Central & Eastern Europe with sell-side research and thus levers our local broker status with excellent company relationships. For corporates in Austria, CEE and Western Europe, we offer co-sponsored research, which includes research coverage and marketing activities to investors. Additionally, through our Spotlight Research product we also shed light on leading European small and micro-caps, seeking greater visibility with investors.
The Institutional Equity Research team consists of roughly 15 analysts, both in Vienna and the CEE countries. Our analysts provide long-standing sector expertise in tandem with profound local market know how and a sectoral approach across the entire region.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.